Cargando…

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process

A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Murillo-Fernández, Mac Arturo, Montero-Zeledón, Ernesto, Abdala-Saiz, Ariadna, Vega-Baudrit, José Roberto, Araya-Sibaja, Andrea Mariela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875139/
https://www.ncbi.nlm.nih.gov/pubmed/35214156
http://dx.doi.org/10.3390/pharmaceutics14020424
_version_ 1784657845778644992
author Murillo-Fernández, Mac Arturo
Montero-Zeledón, Ernesto
Abdala-Saiz, Ariadna
Vega-Baudrit, José Roberto
Araya-Sibaja, Andrea Mariela
author_facet Murillo-Fernández, Mac Arturo
Montero-Zeledón, Ernesto
Abdala-Saiz, Ariadna
Vega-Baudrit, José Roberto
Araya-Sibaja, Andrea Mariela
author_sort Murillo-Fernández, Mac Arturo
collection PubMed
description A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the evaluation of samples retrieved during all stages of a real manufacturing process. Powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetry (TGA), Fourier transform infrared spectroscopy (FT-IR), and contact angle techniques were applied to the samples to determine interactions and incompatibilities. Dissolution tests and long-term stability studies were conducted to evaluate dosage form performance. Results showed weak solid–state interactions able to obtain a eutectic mixture of OLM and HCT while microcrystalline cellulose (MC) impacted the thermal stability of both drugs. Reliable dissolution and long-term stability tests confirmed that the interactions observed were not considered incompatibilities because they were not influenced by the performance of the final products.
format Online
Article
Text
id pubmed-8875139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88751392022-02-26 Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process Murillo-Fernández, Mac Arturo Montero-Zeledón, Ernesto Abdala-Saiz, Ariadna Vega-Baudrit, José Roberto Araya-Sibaja, Andrea Mariela Pharmaceutics Article A drug–drug and drug–excipient interactions and compatibilities study was conducted for two fixed-dose combination (FDC) products containing olmesartan medoxomil (OLM)/hydrochlorothiazide (HCT) 20/12.5 mg and OLM/HCT 40/12.5 mg during their development including storage. The study consisted of the evaluation of samples retrieved during all stages of a real manufacturing process. Powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetry (TGA), Fourier transform infrared spectroscopy (FT-IR), and contact angle techniques were applied to the samples to determine interactions and incompatibilities. Dissolution tests and long-term stability studies were conducted to evaluate dosage form performance. Results showed weak solid–state interactions able to obtain a eutectic mixture of OLM and HCT while microcrystalline cellulose (MC) impacted the thermal stability of both drugs. Reliable dissolution and long-term stability tests confirmed that the interactions observed were not considered incompatibilities because they were not influenced by the performance of the final products. MDPI 2022-02-16 /pmc/articles/PMC8875139/ /pubmed/35214156 http://dx.doi.org/10.3390/pharmaceutics14020424 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Murillo-Fernández, Mac Arturo
Montero-Zeledón, Ernesto
Abdala-Saiz, Ariadna
Vega-Baudrit, José Roberto
Araya-Sibaja, Andrea Mariela
Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
title Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
title_full Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
title_fullStr Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
title_full_unstemmed Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
title_short Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
title_sort interaction and compatibility studies in the development of olmesartan medoxomil and hydrochlorothiazide formulations under a real manufacturing process
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875139/
https://www.ncbi.nlm.nih.gov/pubmed/35214156
http://dx.doi.org/10.3390/pharmaceutics14020424
work_keys_str_mv AT murillofernandezmacarturo interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess
AT monterozeledonernesto interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess
AT abdalasaizariadna interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess
AT vegabaudritjoseroberto interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess
AT arayasibajaandreamariela interactionandcompatibilitystudiesinthedevelopmentofolmesartanmedoxomilandhydrochlorothiazideformulationsunderarealmanufacturingprocess